HGH 191AA (somatropin) benefits and approved uses

Somatropin's documented benefits are the ones written into its FDA labeling: restoring growth in children with defined growth disorders, and correcting body composition and lipid abnormalities in adults with diagnosed growth hormone deficiency. Outside those populations the picture inverts. Growth hormone in healthy older adults and in trained athletes has been put through randomized trials, and the pooled results show small body-composition shifts, no measurable performance gain, and a higher rate of adverse events.

That gap — strong evidence inside the label, weak-to-negative evidence outside it — is the whole story of this molecule, and it is why the marketing language around "HGH 191AA" rarely matches the trial record.

Taking Genotropin as a representative product, the approved indications are narrow and diagnosis-gated (Genotropin label, DailyMed):

• Pediatric: growth failure due to growth hormone deficiency, Prader-Willi syndrome, small for gestational age, Turner syndrome, and idiopathic short stature.
• Adult: adult-onset or childhood-onset growth hormone deficiency.

Nothing on that list is a wellness indication. Every entry describes a measurable deficit — a failure of linear growth, or a pituitary that no longer produces enough GH — that a clinician has to document before treatment begins.

The size of the benefit in diagnosed adult deficiency is quantified. A meta-analysis of 22 randomized, double-blind, placebo-controlled trials (591 GH-treated patients, 562 on placebo) found lean body mass rose 2.61 kg on GH versus 0.04 kg on placebo, fat mass fell 2.19 kg versus a 0.31 kg gain, total cholesterol dropped 0.38 mmol/L, and LDL cholesterol dropped 0.42 mmol/L (PMID 24810900). Notably, the body-composition changes were dose-related while the lipid improvements were not — higher doses moved fat and muscle further but did nothing extra for cholesterol.

The "191AA" in vendor listings refers to the 191-amino-acid sequence of human growth hormone. Recombinant somatropin reproduces that sequence exactly, which is the pharmacological difference between this compound and every growth-hormone secretagogue in the same catalog.

• Secretagogues such as ipamorelin or CJC-1295 ask the pituitary to release its own GH, so somatostatin feedback caps the response.
• Somatropin bypasses the pituitary entirely and acts at GH receptors directly, raising IGF-1 in proportion to the amount given.
• That directness is why somatropin has approvals and secretagogues mostly do not — and equally why its adverse-effect profile scales with dose in a way a secretagogue's does not.

The anti-aging claim has been tested. A systematic review in Annals of Internal Medicine pooled 18 randomized study populations of community-dwelling healthy elderly participants (mean age 69, 220 people receiving GH, 107 person-years of treatment). GH produced a 2.1 kg fall in fat mass and a 2.1 kg rise in lean body mass — but body weight did not change, bone density did not change, and serum lipids other than total cholesterol did not change. Participants on GH were significantly more likely to experience soft-tissue edema, arthralgia, carpal tunnel syndrome, and gynecomastia, and somewhat more likely to develop diabetes or impaired fasting glucose. The authors' conclusion was unambiguous: GH cannot be recommended as an anti-aging therapy (PMID 17227934).

The athletic claim fared no better. A companion review of 27 randomized study samples in young, lean, physically fit participants (mean age 27, 303 GH recipients) found the same 2.1 kg lean-mass increase — and no improvement in strength or exercise capacity. Lactate during exercise was significantly higher in two of the three studies measuring it, and GH recipients reported more soft-tissue edema and fatigue (PMID 18347346).

The recurring 2.1 kg figure is worth sitting with. GH reliably changes what a DXA scan reports. It did not, in either review, change what the participant could do.

Lean-mass gain on a scanner is not the same as function, and a substantial share of the early change reflects fluid retention rather than contractile tissue — which is also why edema and carpal tunnel appear so consistently in the adverse-event columns. Beyond that, the labeled benefits were achieved with pharmaceutical-grade product, weight- or response-titrated dosing, and IGF-1 monitoring; research-chemical vials sold as "HGH 191AA" carry none of those. For the adverse-effect side of the ledger, see the side-effects page.